Access to cancer specialist care and treatment in patients with advanced stage lung cancer

MarketScan and SEER-Medicare databases were analyzed separately to evaluate the access to cancer specialists and treatment of patients with advanced stage lung cancer. Between 4% and 12% of the patients were never seen by a cancer specialist, and between 6% and 10% did not receive cancer-directed therapy. Patients seen by a cancer specialist were more likely to receive cancer-directed therapy.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2pgHXYO
via IFTTT